What Does Verified erinacine A Content Mean for Lion's Mane Mycelium Ingredients?

Nammex Mushrooms will highlight ErinaPrime, a freeze-dried Lion's mane mycelium powder the company had already introduced, at SupplySide Global in Las Vegas from October 28-30, 2026.¹

The ingredient is cultivated through a proprietary submerged liquid fermentation process and, once harvested, is precision freeze-dried rather than grown on a solid grain substrate.¹

The company describes ErinaPrime as standardized to 1% erinacine A, a diterpenoid compound documented in mycelium tissue that has been evaluated in human trials for cognitive and auditory outcomes, with each production batch verified by an outside laboratory.

For finished product manufacturers, the trade show appearance lands in a functional mushroom ingredient category where standardization practices vary considerably and where the compound responsible for a marketed effect is not always present in verifiable amounts.

How Is ErinaPrime Different From Other Lion's Mane Mycelium Ingredients?

According to the company, the proprietary submerged liquid fermentation process is carried out in sterile liquid media rather than on a solid grain substrate, after which the mycelium is separated from the liquid medium and precision freeze-dried post-harvest, a process Nammex says preserves the mycelium's biochemical profile without solvent extraction.

The ingredient is intended to supply erinacine A at a declared 10 mg per gram, verified through third-party testing, distinguishing it from mycelium-on-grain products where the fungal mycelium is not physically separated from its growth substrate before the finished ingredient is sold.

What Does the Underlying Research on Erinacine A Actually Show?

The compound has been examined in a small number of published, peer-reviewed human trials rather than in large confirmatory studies. A 2020 pilot trial in Frontiers in Aging Neuroscience gave adults showing signs of mild cognitive decline three capsules daily supplying roughly 5.25 mg of erinacine A over 49 weeks and reported changes in cognitive test scores and imaging markers relative to placebo.²

A separate 2022 trial in the Journal of Functional Foods followed 59 hearing-impaired adults aged 50 to 79 through an eight-month intervention using boluses supplying 10 mg of erinacine A daily, finding that participants 65 and older who received the mycelia showed better high-frequency hearing thresholds and speech recognition than those on placebo, with no equivalent benefit observed in younger participants.³

A third pilot study published in 2024, involving 33 adults over 8 weeks, reported improvements on 2 non-verbal processing-speed measures alongside changes in gut microbiota composition.⁴ Each of these trials was small, ranging from roughly 30 to 80 participants, and none has yet been replicated at larger scale.

Why Does Standardization Matter More in This Ingredient Category Than Others?

Lion's mane products are broadly marketed for cognitive support, but the compounds responsible for that effect are concentrated in specific fungal tissue and growth conditions rather than present uniformly across any product labeled Lion's mane.

Mycelium grown on grain substrate can retain residual grain material in the finished ingredient, and independent laboratory analyses presented at industry conferences this year have found that some commercial mycelium-on-grain products contain compound profiles resembling their grain substrate rather than the mushroom itself, despite passing DNA-based identity testing due to trace fungal genetic material in the growth medium.

What Should Manufacturers Still Confirm Before Formulating With This Ingredient?

The clinical evidence behind erinacine A remains limited to a handful of small, industry-adjacent pilot trials, and manufacturers should weigh that against the more extensive marketing language often applied to Lion's mane broadly.

Those considering the ingredient for cognitive or auditory health claims should also confirm that any structure-function language matches the specific populations, doses, and outcomes reported in the underlying trials rather than extending those findings to broader claims.

References

1. Nammex to highlight ErinaPrime pure Lion's mane mycelium ingredient free of grain or fillers at SupplySide Global 2026. Press release. Nammex Mushrooms, Inc. September 10, 2026. Accessed September 14, 2026. Press release provided via email.

2. Li IC, Chang HH, Lin CH, et al. Prevention of early Alzheimer's disease by erinacine A-enriched Hericium erinaceus mycelia pilot double-blind placebo-controlled study. Front Aging Neurosci. 2020;12:155. doi:10.3389/fnagi.2020.00155

3. Chan YC, Lin TC, Chen CC, et al. Effects of erinacine A-enriched Hericium erinaceus on elderly hearing-impaired patients: a double-blind, randomized, placebo-controlled clinical trial. J Funct Foods. 2022;97:105220. doi:10.1016/j.jff.2022.105220

4. Černelič Bizjak M, Jenko Pražnikar Z, Kenig S, et al. Effect of erinacine A-enriched Hericium erinaceus supplementation on cognition: a randomized, double-blind, placebo-controlled pilot study. J Funct Foods. 2024;115:106120. doi:10.1016/j.jff.2024.106120